中源协和细胞基因工程股份有限公司关于全资子公司药品临床试验申请取得受理通知书的公告

Group 1 - The core announcement is that the company's wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., has received a notice of acceptance for the clinical trial application of VUM02 injection from the National Medical Products Administration (NMPA) [1] - VUM02 injection is a cryopreserved cell preparation developed by the company, derived from umbilical cord mesenchymal stem cells (UC-MSC), aimed at treating post-pneumonia pulmonary fibrosis [2] - As of June 2025, the total R&D investment for the related project has reached RMB 22.33 million [2]